Atrial fibrillation (AF) is the most common recurrent arrhythmia in clinical practice and the prevalence increases steeply with age, and with common age-associated co-morbidities such as heart failure, coronary artery disease, obesity, hypertension, diabetes and chronic kidney disease. It is associated with increased risk of serious morbidities such as stroke and with death.
Current clinical guidelines recommend direct oral anticoagulants (DOACs) as the treatment of choice to reduce stroke risk in non-valvular AF (NVAF). It is important for clinicians to be confident prescribing these drugs in the spectrum of patients with NVAF.
This program will help improve your skills and knowledge when prescribing DOACs for complex older patients with NVAF in the presence of co-morbidities and polypharmacy, while taking into account and mitigating important risks, such as bleeding and considering appropriate drug selection and dose adjustment.
This program is supported by an independent and unrestricted educational grant by BMS Alliance & Pfizer.